---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-093943"
form_type: "8-K"
ticker: "MGX"
cik: "0001785279"
company_name: "Metagenomi Therapeutics, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:47:56.931767+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Metagenomi reports $160.8M cash, MGX-001 on track for IND in 4Q 2026

## Summary
- Cash, equivalents and marketable securities $160.8M as of Dec 31, 2025; runway through 4Q 2027.
- R&D expenses $94.4M in FY2025 (down 13.6% from FY2024); G&A $26.8M (down 16.3% from $32.0M).
- MGX-001 hemophilia A pre-IND meeting completed; IND filing expected 4Q 2026, clinical trials in 2027.
- Preclinical NHP data showed curative FVIII levels; in vivo proof-of-concept for Antithrombin deficiency also achieved.
- Corporate name changed to Metagenomi Therapeutics; Ionis collaboration advancing APOC3 target in cardiometabolic indications.

## SEC filing metadata
- accession: 0001193125-26-093943
- form_type: 8-K
- ticker: MGX
- cik: 0001785279
- company_name: Metagenomi Therapeutics, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093943/0001193125-26-093943-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093943/mgx-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-093943
- JSON: https://secwatch.observer/filing/0001193125-26-093943.json
- Plain text: https://secwatch.observer/filing/0001193125-26-093943.txt

## Key facts
- Earnings Releases
  Metagenomi Therapeutics, Inc. reported financial results for the full year ended December 31, 2025.
  - Period: the full year ended December 31, 2025
  - Result: reported results
  source text: On March 5, 2026, Metagenomi Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025 and additional business updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785279/000119312526093943/0001193125-26-093943-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.